Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV vaccine for Japanese encephalitis across Asia
New commercialisation agreement builds on existing partnership with Zuellig PharmaSINGAPORE - 16 January 2024 - Zuellig Pharma, a leading health
